Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190329 | 1.00 | DPYD (0.59) | DPYDNPC1GAAPARP1TDO2 | |
| SCHEMBL14405088 | 0.85 | DPYD (0.52) | DPYDNPC1GAAALDH1A1TSHR | |
| SCHEMBL18640327 | 0.81 | DPYD (0.47) | DPYDGAAALDH1A1LMNAATAD2 | |
| SCHEMBL18640328 | 0.81 | DPYD (0.47) | DPYDGAAALDH1A1LMNAATAD2 | |
| SCHEMBL27253388 | 0.80 | DPYD (0.55) | DPYDNPC1GAAALDH1A1TSHR | |
| SCHEMBL933037 | 0.80 | DPYD (0.59) | DPYDGAAALDH1A1TSHRLMNA | |
| SCHEMBL6512588 | 0.80 | DPYD (0.59) | DPYDGAAALDH1A1TSHRLMNA | |
| SCHEMBL190378 | 0.76 | DPYD (0.59) | DPYDGAAALDH1A1TSHRLMNA | |
| SCHEMBL6374591 | 0.76 | DPYD (0.59) | DPYDGAAALDH1A1TSHRLMNA | |
| SCHEMBL6374582 | 0.76 | DPYD (0.59) | DPYDGAAALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-0135587-B2 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-5817786-A | Single-stranded labelled oligonucleotides of preselected sequences | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5668266-A | Synthesis of single-stranded labelled oligonucleotides of preselected sequence | SYNGENE, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5541313-A | Single-stranded labelled oligonucleotides of preselected sequence | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-4948882-A | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis | SYNGENE, INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0135587-B1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
| US-4247544-A | C-5 Substituted uracil nucleosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | DPYD 1765/4885NPC1 256/4885GAA 80/4885 |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | DPYD 35/4885NPC1 3654/4885GAA 1766/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | DPYD 36/4885NPC1 3693/4885GAA 1916/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | DPYD 3848/4885NPC1 1401/4885GAA 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.